The state of health economic and pharmacoeconomic evaluation research in Zimbabwe: A review

Current Therapeutic Research - Clinical and Experimental

Volumn 69, Issue 3, 2008, Pages 268-285

  Gavaza, Paul ^a   Rascati, Karen ^a   Brown, Carolyn ^a   Lawson, Kenneth ^a   Mann, Teresa ^a  

^a UNIVERSITY OF TEXAS AT AUSTIN   (United States)

Author keywords

cost effective analysis; economic evaluation; health economics; pharmacoeconomics; quality assessment; Zimbabwe

Indexed keywords

NEVIRAPINE; NIFEDIPINE; RESERPINE;

ACQUIRED IMMUNE DEFICIENCY SYNDROME; ARTICLE; CLINICAL TRIAL; COST BENEFIT ANALYSIS; COST EFFECTIVENESS ANALYSIS; COST MINIMIZATION ANALYSIS; COST UTILITY ANALYSIS; DATA BASE; DRUG COST; ECONOMIC ASPECT; FINANCIAL MANAGEMENT; HEALTH CARE COST; HEALTH CARE QUALITY; HOME CARE; HUMAN; HUMAN IMMUNODEFICIENCY VIRUS INFECTION; HYPERTENSION; LUNG TUBERCULOSIS; MALARIA; MEDICAL RESEARCH; PRIORITY JOURNAL; SCHISTOSOMIASIS; ZIMBABWE;

EID: 48049095008     PISSN: 0011393X     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.curtheres.2008.06.005     Document Type: Article

References (52)

1. Drummond M., Sculpher M., and Torrance G. Methods for the Economic Evaluation of Health Care Programmes. 3rd ed (2005), Oxford University Press, Oxford, UK
2. Gerard K. Cost-utility in practice: A policy maker's guide to the state of the art. Health Policy 21 (1992) 249-279
3. Udvarhelyi I., Colditz G., Rai A., and Epstein A. Cost-effectiveness and cost-benefit analyses in the medical literature. Are the methods being used correctly?. Ann Intern Med. 116 (1992) 238-244
4. Adams M., McCall N., Gray D., et al. Economic analysis in randomized control trials. Med Care 30 (1992) 231-243
5. Hill S., Mitchell A., and Henry D. Problems with the interpretation of pharmacoeconomic analyses: A review of submissions to the Australian Pharmaceutical Benefits Scheme. JAMA 283 (2000) 2116-2121
6. Colmenero F., Sullivan S., Palmer J., et al. Quality of clinical and economic evidence in dossier formulary submissions. Am J Manag Care 13 (2007) 401-407
7. Walker D., and Fox-Rushby J. Economic evaluation of communicable disease interventions in developing countries: A critical review of the published literature. Health Econ 9 (2000) 681-698
8. Lee K., Brouwer W., Lee S., and Koo H. Introducing economic evaluation as a policy tool in Korea: Will decision makers get quality information? A critical review of published Korean economic evaluations. PharmacoEconomics 23 (2005) 709-721
9. Robinson S. A tale of two countries (2002). http://www.time.com/time/printout/0,8816,203620,00.html Accessed May 24, 2008
10. Hansen K., Chapman G., Chitsike I., et al. The costs of HIV/AIDS care at government hospitals in Zimbabwe. Health Policy Plan 15 (2000) 432-440
11. Zimbabwe: Demographic and health survey, 2005-2006. Preliminary report (2006), Central Statistical Office and ORC Macro, Harare, Zimbabwe
12. Bvochora J., Kasilo O., and Nhachi C. Disease pattern and prescribing at the University of Zimbabwe students health service, 1987-1991. Cent Afr J Med. 39 (1993) 88-95
13. Hore R. AIDS and private health costs in Zimbabwe. SAfAIDS News 5 (1997) 2-6
14. Hore R. Zimbabwe: Are the costs of AIDS medical care affordable?. AIDS Anal Afr. 3 (1993) 6-8
15. Mitchell M., Littlefield J., and Gutter S. Costing of reproductive health services. Int Fam Plan Perspect 25 (1999) S17-S21
16. Mitchell M., Littlefield J., and Gutter S. Costing of reproductive health services. Int Fam Plan Perspect 25 (1999) S29
17. Drummond M., and Stoddart G. Torrance GW Methods for the Economic Evaluation of Health Care Programmes (1987), Oxford University Press, Oxford, UK
18. Sullivan S., Lyles A., Luce B., and Grigar J. AMCP Guidance for submission of clinical and economic evaluation data to support formulary listing in U.S. health plans and pharmacy benefits management organizations. J Manag Care Pharm 7 (2001) 272-282
19. Zarnke K., Levine M., and O'Brien B. Cost-benefit analysis in the health care literature: Don't judge a study by its label. J Clin Epidemiol. 50 (1997) 817-822
20. Offman J., Sullivan S., Neumann P., et al. Examining the value and quality of health economic analyses: Implications of utilizing the QHES. J Manag Care Pharm. 9 (2003) 53-61
21. Chisadza E., Maponga C., and Nazerali H. User fees and drug pricing policies: A study at Harare Central Hospital, Zimbabwe. Health Policy Plan 10 (1995) 319-326
22. Gomo E., Ndamba J., Murahwa S., et al. In vitro activity of several antimicrobial agents against Neisseria gonorrhoeae and comparison of cost of treatment. Cent Afr J Med. 41 (1995) 83-86
23. Hansen K., Woelk G., Jackson H., et al. The cost of home-based care for HIV/AIDS patients in Zimbabwe. AIDS Care 10 (1998) 751-759
24. Harvey P. The impact of condom prices on sales in social marketing programs. Stud Fam Plan 25 (1994) 52-58
25. Hongoro C., and McPake B. Hospital costs of high-burden diseases: Malaria and pulmonary tuberculosis in a high HIV prevalence context in Zimbabwe. Trop Med Int Health. 8 (2003) 242-250
26. Hore R. The impact of AIDS on direct health care costs in Zimbabwe. AIDS Anal Afr 7 (1997) 8-9
27. Kravitz J., and Sanders D. Paediatric pneumonia in Zimbabwe: Management and pharmaceutical costs of inpatient care. J Trop Pediatr 40 (1994) 17-23
28. McFarland W., Kahn J., Katzenstein D., et al. Deferral of blood donors with risk factors for HIV infection saves lives and money in Zimbabwe. J Acquir Immune Defic Syndr Hum Retrovirol. 9 (1995) 183-192
29. McPake B., and Hongoro C. Contracting out of clinical services in Zimbabwe. Soc Sci Med. 41 (1995) 13-24
30. Manyemba J. A randomised crossover comparison of reserpine and sustained-release nifedipine in hypertension. Cent Afr J Med. 43 (1997) 344-349
31. Palmer D., Mason P., Pasi C., and Tobiwa O. Value of mandatory testing for human immunodeficiency virus in a sub-Saharan hospital population. Clin Infect Dis. 31 (2000) 1258-1265
32. Ndamba J., Makura O., Gwatirisa P., et al. A cost effective two step rapid diagnosis of urinary schistosomiasis in Zimbabwe. Cent Afr J Med. 44 (1998) 167-171
33. Nhachi F., Kasilo O., Mutengezanwa A., and Zvandaziva E. Drug utilisation, supply and expenditure at Chitungwiza, Gweru, Mpilo, Parirenyatwa and United Bulawayo Hospitals in one year (1987-1988). Cent AfrJ Med. 37 (1991) 159-167
34. Sweat M., O'Reilly K., Schmid G., et al. Cost-effectiveness of nevirapine to prevent motherto-child HIV transmission in eight African countries. AIDS 18 (2004) 1661-1671
35. Vander Plaetse B., Hlatiwayo G., Van Eygen L., et al. Costs and revenue of health care in a rural Zimbabwean district. Health Policy Plan 20 (2005) 243-251
36. Vos J., Borgdorff M., and Kachidza E. Cost and output of mobile clinics in a commercial farming area in Zimbabwe. Soc Sci Med. 31 (1990) 1207-1211
37. Verkuyl D. Economics of anti-rhesus prophylaxis in an African population. Cent Afr J Med. 33 (1987) 32-37
38. Waterkeyn J., and Caimcross S. Creating demand for sanitation and hygiene through Community Health Clubs: A cost-effective intervention in two districts in Zimbabwe. Soc Sci Med. 61 (2005) 1958-1970
39. Watts R. Low-cost water supplies and their contribution to health. Afr Health. 15 (1992) 10-11
40. Janowitz B., Johnson L., Thompson A., et al. Excess capacity and the cost of adding services at family planning clinics in Zimbabwe. Int Fam Plan Perspect. 28 (2002) 58
41. Chishawa O., Ziyambi Z., Ndhlovu P., et al. Comparative evaluation and assessment of the diagnostic usefulness of four commercial HIV-1/HIV-2 antibody assays using two well-characterized serum panels from Blood Transfusion Service and the National Health Laboratory Services in Zimbabwe. Cent Afr J Med. 47 (2001) 1-8
42. Dzvaka SK, Gavaza P, Mukosera KT; Zimbabwe community pharmacists' opinions on continuing education: The case of Harare community pharmacists. East Cent Afr J Pharma Sci. In press.
43. Teerawattananon Y., Russell S., and Mugford M. A systematic review of economic evaluation literature in Thailand: Are the data good enough to be used by policy-makers?. PharmacoEconomics 25 (2007) 467-479
44. Maynard A. Developing the health care market. Economics journal 101 (1991) 1277-1286
45. Canadian Coordinating Office of Health Technology Assessment (CCOHTA). Guidelines for Economic Evaluation of Pharmaceuticals. 2nd ed (1997), CCOHTA Publications, Ottawa, Ontario, Canada
46. Commonwealth Department of Health HaCS. Guidelines for the Pharmaceutical Industry on Preperation of Submissions to the Pharmaceutical Benefits Advisory Committee (1995), Australian Government Publishing Service, Canberra, Australia
47. Elixhauser A., Luce B., Taylor W., and Reblando J. Health-care CBA/CEA-an update on the growth and composition of the literature. Med Care 31 (1993) JS1-JS11
48. Hjelmgren J., Berggren F., and Andersson F. Health economic guidelines-similarities, differences and some implications. Value Health 4 (2001) 225-250
49. Neumann P., Stone P., Chapman R., et al. The quality of reporting in published cost-utility analyses, 1976-1997. Ann Intern Med. 132 (2000) 964-972
50. Gerard K., Smoker I., and Seymour J. Raising the quality of cost-utility analyses: Lessons learnt and still to learn. Health Policy 46 (1999) 217-238
51. Garcia-Altes A. Twenty years of health care economic analysis in Spain: Are we doing well?. Health Econ. 10 (2001) 715-729
52. Bell C., Urbach D., Ray J., et al. Bias in published cost effectiveness studies: Systematic review. BMJ 332 (2006) 699-703